Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Iowa Spravato Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.02.77

    Spravato (esketamine) Nasal Spray

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.77 alerts

    Get alerted when Policy 05.02.77 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical necessity determinations for Spravato (esketamine) nasal spray for adults with treatment-resistant depression or major depressive disorder with acute suicidal ideation or behavior, subject to applicable clinical criteria, documentation, supervision, monitoring, and exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicySpravato (esketamine) Nasal Spray
    Policy CodePolicy 05.02.77
    Change TypeNo material change
    Effective DateSep 17, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and administer Spravato through the SPRAVATO REMS program under direct supervision with at least 2 hours of monitoring.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum member age
    2 hoursPost-administration monitoring

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Required antidepressant trials for TRD
    8 weeksMinimum duration of each trial
    8 kitsInitial treatment quantity limit
    3 monthsTRD authorization period

    Coverage Criteria

    Initial Therapy

    Initial authorization may be granted for 3 months for treatment-resistant depression (TRD) or for 1 month for major depressive disorder (MDD) with acute suicidal ideation or behavior when ALL of the following criteria are met.

    ALL of the following

    • Member has a confirmed diagnosis of severe major depressive disorder, single or recurrent episode, documented by standardized rating scales that reliably measure depressive symptoms, such as the Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Rating Scale (MADRS), or Patient Health Questionnaire-9 (PHQ-9).
    • Diagnosis is verified by a psychiatrist or a psychiatric or mental health nurse practitioner.
    • Spravato is prescribed by, or in consultation with, a psychiatrist, or prescribed by a psychiatric or mental health nurse practitioner.
    • Member is 18 years of age or older.
    • Requested drug will be administered under the direct supervision of a healthcare provider.
    • Member will be monitored by a healthcare provider for at least 2 hours after administration.
    • ONE of the following pathways

      • TRD pathway

        • Member has treatment-resistant depression (TRD), defined as an inadequate response during the current depressive episode to two antidepressants from at least two different classes, with different mechanisms of action, at the maximally tolerated labeled dose, with each antidepressant used for at least 8 weeks.

          Antidepressant classes may include aminoketones such as bupropion; monoamine oxidase inhibitors (MAOIs); noradrenaline and specific serotoninergic antidepressants (NASSAs); selective serotonin reuptake inhibitors (SSRIs); serotonin-norepinephrine reuptake inhibitors (SNRIs); tricyclic antidepressants (TCAs); and serotonin modulators. Examples listed in the policy include Wellbutrin/SR/XL; Marplan, Nardil, Parnate, phenelzine, and tranylcypromine; amoxapine, maprotiline, mirtazapine/ODT, Oleptro ER, Remeron/Solutab, trazodone; Celexa, citalopram, escitalopram, fluoxetine, fluvoxamine, Lexapro, Luvox/CR, paroxetine, Paxil/CR, Pexeva, Prozac/Weekly, sertraline, and Zoloft; Cymbalta, desvenlafaxine/ER, duloxetine, Effexor/XR, Fetzima, Irenka, Khedezla, Pristiq, and venlafaxine/ER; amitriptyline, desipramine, doxepin, Elavil, imipramine, Norpramin, nortriptyline, Pamelor, Surmontil, Tofranil, and trimipramine; and Trintellix, vortioxetine, Viibryd, and vilazodone.

        • ONE of the following must also be met

          • Member has experienced an inadequate response with an adequate trial of augmentation therapy during the current depressive episode.

            Augmentation therapy is defined as two antidepressants with different mechanisms of action used concomitantly; an antidepressant and a second-generation antipsychotic used concomitantly; an antidepressant and lithium used concomitantly; an antidepressant and thyroid hormone used concomitantly; or an antidepressant and buspirone used concomitantly.

    Continuation Therapy

    Authorization of 3 months may be granted for continuation of treatment of TRD when ALL of the following criteria are met:

    ALL of the following

    • There is an improvement or sustained improvement from baseline in depressive symptoms documented by standardized rating scales that reliably measure depressive symptoms, such as the Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Rating Scale (MADRS), or Patient Health Questionnaire-9 (PHQ-9).
    • If duration of use is greater than 4 months, dosing frequency has been individualized to the least frequent dosing needed to maintain remission or response.
    • Requested drug will continue to be administered under the direct supervision of a healthcare provider.
    • Requested drug must be prescribed by, or in consultation with, a psychiatrist, or prescribed by a psychiatric or mental health nurse practitioner.

    Not Medically Necessary

    Use of Spravato is not medically necessary when the applicable coverage criteria are not met.

    Not medically necessary when ANY of the following applies

    • Member does not meet the initial therapy criteria for TRD or MDD with acute suicidal ideation or behavior.
    • Member does not meet the continuation therapy criteria for TRD.
    • Requested use is otherwise unsupported by the criteria set forth in this policy.

    Coverage will not be provided for members with moderate or severe substance or alcohol use disorder that is not currently being treated or medically managed.

    Spravato is not approved as an anesthetic agent. The safety and effectiveness of Spravato as an anesthetic agent have not been established.

    Spravato is considered not medically necessary for members who do not meet the criteria set forth above.

    The use of Spravato, in conjunction with an oral antidepressant, beyond 4 weeks has not been systematically evaluated in the treatment of depressive symptoms in patients with MDD with acute suicidal ideation or behavior. Such use is not supported under this policy.

    Coding and Billing

    Provider services and billing codesHCPCS
    J0013Esketamine, nasal spray, 1 mg (effective 1/1/2026)
    J3490Unclassified drugs
    J3590Unclassified biologics
    S0013Esketamine, nasal spray, 1 mg (cancelled 12/31/25)
    G2082Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of up to 56 mg of esketamine nasal self-administration, includes 2 hours post-administration observation
    G2083Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation
    Post-administration observation
    Required observation periodAt least 2 hours after administration
    Administration settingOffice or other outpatient visit under supervision of a physician or other qualified healthcare professional
    Billing inclusionG2082 and G2083 include 2 hours of post-administration observation
    Esketamine dose threshold
    Lower-dose serviceG2082 applies to provision of up to 56 mg of esketamine nasal self-administration
    Higher-dose serviceG2083 applies to provision of greater than 56 mg of esketamine nasal self-administration

    Provider Requirements and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initial and continuation requests. Submit documentation supporting the applicable diagnosis, prescribing or consultation requirements, treatment response, and clinical circumstances.

    • For initial requests, document the diagnosis and consultation when the prescriber is not a psychiatrist or psychiatric or mental health nurse practitioner.
    • For MDD with acute suicidal ideation or behavior, document current suicidal ideation with intent and the prescriber’s representation that, without Spravato, acute psychiatric hospitalization will be required within 24 to 48 hours.
    • For continuation requests, submit current and baseline depression severity scores and consultation records when the prescriber is not a psychiatrist or psychiatric or mental health nurse practitioner.
    Prior Authorization

    Initial Authorization Duration

    Initial authorization may be granted for the applicable indication only when all coverage criteria are met.

    • Treatment-resistant depression (TRD): authorization may be granted for 3 months.

    Background

    Spravato (esketamine) is the S-enantiomer of racemic ketamine and a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. It is used in adults with treatment-resistant depression and for depressive symptoms associated with major depressive disorder and acute suicidal ideation or behavior, with an oral antidepressant where specified. Because of risks including sedation, dissociation, abuse, misuse, and suicidal thoughts or behaviors, Spravato is available through the restricted SPRAVATO Risk Evaluation and Mitigation Strategy (REMS) program and requires direct supervision with at least 2 hours of monitoring.

    Definitions

    Treatment-resistant depression (TRD)
    Current episodeThe inadequate response must occur during the current depressive episode
    Antidepressant trialsInadequate response to two antidepressants from at least two different classes or mechanisms of action, each at the maximally tolerated labeled dose for at least 8 weeks
    Additional treatmentInadequate response to an adequate augmentation-therapy trial or evidence-based psychotherapy is also required
    Augmentation therapy
    Two-antidepressant combinationTwo antidepressants with different mechanisms of action used concomitantly
    Antipsychotic combinationAn antidepressant and a second-generation antipsychotic used concomitantly

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial authorization may be granted for 3 months for treatment-resistant depression or 1 month for MDD with acute suicidal ideation or behavior when all general requirements and one qualifying indication pathway are met.

    General requirements: The member has severe major depressive disorder documented by a reliable standardized rating scale; the diagnosis is verified by a psychiatrist or psychiatric or mental health nurse practitioner; the drug is prescribed by or in consultation with a psychiatrist or by a psychiatric or mental health nurse practitioner; the member is at least 18 years old; administration is under direct healthcare-provider supervision; and monitoring continues for at least 2 hours after administration.Age >= 18; monitoring >= 2 hours

    Indication-specific requirements

    • Treatment-resistant depression: During the current depressive episode, the member has had an inadequate response to two antidepressants from at least two different classes at maximally tolerated labeled doses, with each trial lasting at least 8 weeks, and has had an inadequate response to an adequate trial of augmentation therapy or evidence-based psychotherapy.

    Continuation Criteria

    Treatment-Resistant Depression Continuation

    Continuation authorization for treatment-resistant depression may be granted for 3 months when all criteria are met.

    Treatment-resistant depression continuation: Depressive symptoms have improved or remained improved from baseline on a standardized rating scale; after more than 4 months of use, dosing is individualized to the least frequent schedule that maintains remission or response; administration remains under direct healthcare-provider supervision; and prescribing continues by or in consultation with a psychiatrist or by a psychiatric or mental health nurse practitioner.Use > 4 months requires least-frequent effective dosing

    Step Therapy Requirements

    StepRequired treatmentCoverage requirement
    1Two antidepressants from at least two different classes or mechanisms of action, each at the maximally tolerated labeled dose, followed by augmentation therapy or evidence-based psychotherapy.The member must have an inadequate response during the current depressive episode to each antidepressant trial, with each trial lasting at least 8 weeks, and an inadequate response to an adequate trial of augmentation therapy or evidence-based psychotherapy. Evidence-based psychotherapy includes cognitive behavioral therapy, interpersonal therapy, supportive therapy, or psychoeducational intervention.

    Quantity Limits

    Quantity limit — initiation
    ProductSpravato nasal spray 56 mg Dose Kit or 84 mg Dose Kit
    Applicable useTreatment-resistant depression initiation of therapy
    Quantity limit8 kits per first 28 days
    Quantity limit — maintenance
    ProductSpravato nasal spray 56 mg Dose Kit or 84 mg Dose Kit
    Applicable useTreatment-resistant depression maintenance therapy
    Quantity limit4 kits per 28 days

    Site of Care and Monitoring

    Note

    Provide required supervision and monitoring

    Administer Spravato under the direct supervision of a healthcare provider and monitor the member for at least 2 hours after administration.

    Billing Rule

    Meet office administration requirements

    For office administration, direct supervision must be provided by a physician or other qualified healthcare professional, with at least 2 hours of post-administration observation.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicySpravato (esketamine) Nasal Spray
    Policy CodePolicy 05.02.77
    Change TypeNo material change
    Effective DateSep 17, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and administer Spravato through the SPRAVATO REMS program under direct supervision with at least 2 hours of monitoring.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Requirements and AuthorizationBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy RequirementsQuantity LimitsSite of Care and Monitoring
  1. Member has experienced an inadequate response to evidence-based psychotherapy during the current depressive episode.

    Evidence-based psychotherapy includes cognitive behavioral therapy (CBT), interpersonal therapy (IPT), supportive therapy (ST), or psychoeducational intervention (PEI).

  2. MDD with acute suicidal ideation or behavior pathway

    • Member has major depressive disorder with current suicidal ideation with intent, defined as both of the following: the member has thoughts, even momentarily, of self-harm with at least some intent or awareness that they may die as a result, or thinks about suicide; and the member intends to act on thoughts of killing themselves.
    • The prescriber represents that, in the absence of the requested drug, the member will require confinement in an acute care psychiatric institution within the next 24 to 48 hours.
    • Requested drug will be used in combination with an oral antidepressant, such as duloxetine, escitalopram, sertraline, or venlafaxine.
  3. Observation included
    Both services include 2 hours of post-administration observation
  4. Major depressive disorder (MDD) with acute suicidal ideation or behavior: authorization may be granted for 1 month.
  5. For MDD with acute suicidal ideation or behavior, Spravato must be used with an oral antidepressant.
  6. Prior Authorization

    TRD Continuation Authorization

    Continuation authorization for TRD may be granted for 3 months when the member demonstrates improvement or sustained improvement from baseline on standardized depression rating scales and all continuation requirements are met.

    • If treatment exceeds 4 months, dosing frequency must be individualized to the least frequent schedule that maintains remission or response.
    • Treatment must continue under direct healthcare-provider supervision.
    • The drug must be prescribed by, or in consultation with, a psychiatrist or prescribed by a psychiatric or mental health nurse practitioner.
    Billing Rule

    REMS and Direct Supervision Required

    Spravato is available only through the SPRAVATO Risk Evaluation and Mitigation Strategy (REMS) restricted program because of risks including sedation, dissociation, abuse, misuse, and suicidal thoughts and behaviors. The provider must administer Spravato under direct supervision and monitor the member for at least 2 hours after administration.

    • Administration must comply with the SPRAVATO REMS restricted-program requirements.
    • Direct supervision by a healthcare provider is required for every administration.
    • The member must be monitored by a healthcare provider for a minimum of 2 hours after administration.

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Other qualifying combinationsAn antidepressant used concomitantly with lithium, thyroid hormone, or buspirone
    Current suicidal ideation with intent
    Self-harm or suicide thoughtsThoughts, even momentarily, of self-harm with at least some intent or awareness that death may result, or thoughts about suicide
    Intent to actIntent to act on thoughts of killing oneself
    Required elementsBoth thoughts with at least some intent or awareness of possible death and intent to act are required
    Treatment-resistant depression
    Core descriptionDepression that does not respond to multiple therapeutic courses of antidepressant medications
    Proposed treatment thresholdFailure of two adequate therapeutic courses of antidepressants or psychotherapy from different classes
    Timing and sequencingThe courses may be given in combination or succession during the current episode
    SPRAVATO REMS
    Program nameSPRAVATO Risk Evaluation and Mitigation Strategy (REMS)
    Access requirementSpravato is available only through this restricted program
    Risks addressedThe program addresses risks including sedation, dissociation, abuse and misuse, and suicidal thoughts and behaviors
    2 antidepressants; 2 different classes; >= 8 weeks each
  7. MDD with acute suicidal ideation or behavior: The member has MDD with current suicidal ideation with intent; the prescriber represents that, without Spravato, acute psychiatric confinement will be required within 24 to 48 hours; and Spravato will be used in combination with an oral antidepressant.Potential confinement within 24-48 hours
  8. Quantity limit — acute suicidal ideation or behavior
    ProductSpravato nasal spray 56 mg Dose Kit or 84 mg Dose Kit
    Applicable useMajor depressive disorder with acute suicidal ideation or behavior
    Quantity limit8 kits per 28-day course of therapy